Home › NDC Lookup › RxCUI directory › RxCUI 401938

Miglustat 100 MG Oral Capsule — RxCUI 401938

Name: Miglustat 100 MG Oral Capsule (RxCUI 401938)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 401938 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI401938

Official nameMiglustat 100 MG Oral Capsule

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped6

Package NDCs mapped7

Reported Medicaid activity (SDUD)118 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Miglustat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It depends on the product. Miglustat, Zavesca and Yargesa treat mild to moderate type 1 Gaucher disease in adults who can't use enzyme replacement therapy. Opfolda is used with Pom...
Food slows how fast miglustat is absorbed but doesn't change much how much your body takes in. If you get diarrhea, taking the capsules between meals may help. Follow your prescrib...
Diarrhea and weight loss are very common, and many people notice gas, stomach pain, nausea, headache or shaky hands. Diarrhea often improves over time and may respond to diet chang...
Call if you feel numbness, tingling, pain or weakness in your hands or feet. Also call for a tremor that doesn't go away or diarrhea and weight loss that keep going. Your doctor wi...

📖 Read our full Miglustat guide →

🕸️ Concept Web — How Miglustat 100 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Miglustat 100 MG Oral Capsule RxCUI 401938 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Miglustat 402316 IN
Brand names 2

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Yargesa 2642345 BN
- Zavesca 356766 BN
Dose forms 12

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Miglustat Oral Capsule 402347 SCDF
- Miglustat Oral Product 1164725 SCDG
- Miglustat Pill 1164726 SCDG
- Miglustat Oral Capsule [Yargesa] 2642349 SBDF
- Miglustat Oral Capsule [Zavesca] 541069 SBDF
- Yargesa Oral Product 2642347 SBDG
- Yargesa Pill 2642348 SBDG
- Zavesca Oral Product 1187052 SBDG
- +4 more in this family
Clinical & branded drugs 5

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Miglustat 100 MG 402346 SCDC
- Miglustat 100 MG Oral Capsule [Yargesa] 2642350 SBD
- Miglustat 100 MG Oral Capsule [Zavesca] 541070 SBD
- Miglustat 100 MG [Yargesa] 2642346 SBDC
- Miglustat 100 MG [Zavesca] 541068 SBDC

Showing up to 8 concepts per family — 16 of 20 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Miglustat 100 MG SCDC · 402346
Miglustat Oral Capsule SCDF · 402347
Miglustat Oral Product SCDG · 1164725
Miglustat Pill SCDG · 1164726

Brand-Name Concepts

Miglustat 100 MG Oral Capsule [Yargesa] SBD · 2642350
Miglustat 100 MG Oral Capsule [Zavesca] SBD · 541070
Miglustat 100 MG [Yargesa] SBDC · 2642346
Miglustat 100 MG [Zavesca] SBDC · 541068
Miglustat Oral Capsule [Yargesa] SBDF · 2642349
Miglustat Oral Capsule [Zavesca] SBDF · 541069
Yargesa Oral Product SBDG · 2642347
Yargesa Pill SBDG · 2642348
Zavesca Oral Product SBDG · 1187052
Zavesca Pill SBDG · 1187053

📦 FDA Products & Package NDCs

6 products · 7 package NDCs

7 package NDCs map to RxCUI 401938 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
10148-0201-90	6 BLISTER PACK in 1 CARTON (10148-201-90) / 15 CAPSULE in 1...	Miglustat	CoTherix, Inc.	2018-04-25
42799-0709-15	1 BLISTER PACK in 1 CARTON (42799-709-15) / 15 CAPSULE in 1...	Yargesa	Edenbridge Pharmaceuticals LLC.	2023-10-31
43975-0310-83	6 BLISTER PACK in 1 CARTON (43975-310-83) / 15 CAPSULE in 1...	MIGLUSTAT	ANI Pharmaceuticals, Inc.	2018-04-17
66215-0201-90	6 BLISTER PACK in 1 CARTON (66215-201-90) / 15 CAPSULE in 1...	Zavesca	Actelion Pharmaceuticals US, Inc.	2003-07-31
68475-0204-02	6 BLISTER PACK in 1 CARTON (68475-204-02) / 15 CAPSULE in 1...	Miglustat	Navinta LLC	2025-05-07
68475-0204-04	4 BLISTER PACK in 1 CARTON (68475-204-04) / 21 CAPSULE in 1...	Miglustat	Navinta LLC	2025-12-23
70710-2039-08	6 BLISTER PACK in 1 CARTON (70710-2039-8) / 15 CAPSULE in 1...	Miglustat	Zydus Pharmaceuticals USA Inc.	2025-04-01

Observed labelers: Navinta LLC (2) · Actelion Pharmaceuticals US, Inc. (1) · ANI Pharmaceuticals, Inc. (1) · CoTherix, Inc. (1) · Edenbridge Pharmaceuticals LLC. (1) · Zydus Pharmaceuticals USA Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.